Study guide

10.3 Naloxone and Opioid Antagonist Access

Connecticut Multistate Pharmacy Jurisprudence Examination CT MPJE

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 About the Connecticut MPJE 1.2 Application, Fees, ATT, and Pearson VUE 1.3 Blueprint, Scoring, Retakes, and Study Strategy

2 Connecticut Regulatory Structure

2.1 DCP and the Commission of Pharmacy 2.2 Chapter 400j, 420b/420c, and RCSA 20-576 2.3 Federal vs Connecticut Law (More Restrictive Rule)

3 Pharmacist Licensure, Interns, PIC, and CE

3.1 Pharmacist Qualifications and Exam Path 3.2 Interns, Score Transfer, and Reciprocity 3.3 Pharmacist-in-Charge / Pharmacist Manager 3.4 License Renewal and Continuing Education

4 Technicians and Non-Pharmacist Personnel

4.1 Technician Registration and Certification 4.2 Community Technician Ratios (20-576-36) 4.3 Institutional Ratios and Advanced Pharmacy Technicians 4.4 Technician Limitations, Interns, and Unlicensed Staff

5 Discipline, Impairment, and Unlicensed Practice

5.1 Disciplinary Grounds (CGS § 20-579) 5.2 Impaired Practitioner Reporting and Programs 5.3 Unlicensed Practice, Penalties, and Appeals

6 Federal Drug Law Foundations

6.1 FDCA, Adulteration, and Misbranding 6.2 FDA Approval, Recalls, and OTC vs Rx 6.3 DSCSA, HIPAA, OBRA ’90, and PPPA

7 Federal Controlled Substances

7.1 CSA Schedules and Definitions 7.2 DEA Registration and Forms 222, 106, 41 7.3 Federal Controlled-Substance Prescription Rules 7.4 Inventory, Theft, Loss, and Disposal

8 Prescription Issuance in Connecticut

8.1 Who May Prescribe in Connecticut 8.2 Noncontrolled Prescription Form and Content 8.3 Controlled Prescriptions and the EPCS Mandate

9 Refills, Partial Fills, and Opioid Limits

9.1 Refill Authority (Noncontrolled and CIII–V) 9.2 Partial Fills of Schedule II Prescriptions 9.3 Connecticut Opioid Supply Limits (7-day / 5-day)

10 Administration, CDTM, and Standing Orders

10.1 Pharmacist Immunization Authority 10.2 Collaborative Drug Therapy Management 10.3 Naloxone and Opioid Antagonist Access 10.4 Emergency and Hormonal Contraception

11 Counseling, Confidentiality, and Returns

11.1 Counseling and Offer to Counsel 11.2 HIPAA and Connecticut Confidentiality 11.3 Return, Reuse, and Take-Back

12 Corresponding Responsibility and DUR

12.1 Corresponding Responsibility and Legitimate Medical Purpose 12.2 Prospective Drug Utilization Review 12.3 Exceptions and Conditions Prohibiting Dispensing

13 Transfers, Labeling, Packaging, and Delivery

13.1 Transferring Prescriptions 13.2 Labeling of Dispensed Drugs 13.3 Packaging and the Poison Prevention Packaging Act 13.4 Delivery of Drugs

14 CPMRS, Substitution, and Nonprescription Drugs

14.1 CPMRS Query and Reporting 14.2 Generic and Biosimilar Substitution 14.3 CMEA and Behind-the-Counter Products 14.4 OTC Labeling, Hazardous, and Restricted Nonprescription Drugs

15 Ordering, Records, and Inventories

15.1 Ordering and Acquisition (DEA 222/CSOS) 15.2 Distribution and DSCSA Records 15.3 Recordkeeping Content and Three-Year Retention 15.4 Controlled-Substance Inventories and CT Perpetual CII

16 Storage, Security, and Hazardous Drugs

16.1 Controlled-Substance Storage and Security 16.2 Hazardous Drugs (USP <800>, NIOSH) 16.3 Non-Pharmacist Access to Drugs

17 Compounding and Central Fill

17.1 Nonsterile Compounding (USP <795>, RCSA 20-576-69) 17.2 Sterile Compounding (USP <797>, RCSA 20-576-64) 17.3 Central Fill, 503A, and 503B Outsourcing

18 Pharmacy Permits and Practice Settings

18.1 Pharmacy License, Hours, Manager, and Signage 18.2 Nonresident, Hospital, Nuclear, and Automated Dispensing 18.3 Inspection, Closure, and Facility Discipline

10.3 Naloxone and Opioid Antagonist Access

Key Takeaways Explain This Topic AI

CGS § 20-633c lets a pharmacist who is trained and certified by a DCP-approved program prescribe an opioid antagonist in good faith, train the recipient, and keep a dispensing-and-training record; that prescribing authority may not be delegated.

CGS § 20-633d is different: a prescribing practitioner and a pharmacy may file with DCP a medical protocol standing order so a similarly certified pharmacist may dispense FDA-approved intranasal or auto-injector opioid antagonist to a person at risk or to a family member, friend, or other person in a position to assist, and must send a copy of the dispensing record to that practitioner.

P.A. 23-97 added CGS § 20-14o(f)(2): when issuing an opioid-drug prescription, the prescribing practitioner shall encourage the patient (and, if applicable, a present parent or guardian of a minor) to obtain an opioid antagonist.

P.A. 23-52 expanded CGS § 21a-286 so a § 20-633c-certified pharmacist or a prescribing practitioner may agree with a host agency (including local law enforcement, EMS, government, community health, or a board of education) to stock public secure boxes or nasal-antagonist vending machines.

Pharmacists who prescribe under § 20-633c or dispense under § 20-633d are deemed not to have violated a pharmacist standard of care; § 21a-286(f) adds civil, administrative, and criminal immunity for the pharmacist or practitioner as to the host agency’s later administration or dispensing.

Last updated: August 2026

10.3 Naloxone and Opioid Antagonist Access

Quick Answer: Prescribe under CGS § 20-633c . Dispense under a standing order under CGS § 20-633d . Both require a pharmacist trained and certified by a DCP-approved program , recipient training , and a record . § 20-633c cannot be delegated. P.A. 23-97 added CGS § 20-14o(f)(2) : the prescribing practitioner who issues an opioid-drug prescription shall encourage the patient to obtain an opioid antagonist . P.A. 23-52 expanded CGS § 21a-286 so a certified pharmacist may agree with a host agency (police, EMS, government, community health, school board) to install public secure boxes or nasal-antagonist vending machines .

NABP Competency 2.2 will mix these files. A stem that says “the technician will just prescribe Narcan” fails § 20-633c(d) . A stem that says “Connecticut has no standing-order path, only pharmacist prescribing” fails § 20-633d . A stem that says “pharmacists may only sell FDA’s OTC naloxone spray” ignores both statutes.

Prescribe versus dispense under protocol — two statutes

Feature CGS § 20-633c (prescribe) CGS § 20-633d (standing-order dispense)

Who is the prescriber? The certified pharmacist , in good faith A prescribing practitioner (CGS § 20-14c) who is authorized to prescribe an opioid antagonist; the pharmacy holds the agreement

What product? An opioid antagonist as defined in CGS § 17a-714a FDA-approved antagonist given by intranasal application or auto-injection

To whom? Not limited by a “person at risk” clause in § 20-633c itself Any person at risk of opioid overdose, or a family member, friend, or other person in a position to assist

Training of the pharmacist DCP-approved train-and-certify program Same: DCP-approved program

Training of the recipient Required , plus a dispensing-and-training record Required , plus the record, and a copy of the dispensing record sent to the standing-order practitioner

Filing with DCP Certification through the approved program The pharmacy shall provide DCP a copy of every standing-order agreement

Delegation No. The pharmacist may not delegate or direct any other person to prescribe or to train the recipient under subsection (a) Dispensing is still the pharmacist’s certified act under the protocol

Standard of care Deemed not to have violated any pharmacist standard of care Same deeming language

§ 20-633d(b) says the standing order shall be deemed issued for a legitimate medical purpose in the usual course of the prescribing practitioner’s professional practice . That sentence is how a non-patient-specific protocol still satisfies corresponding-responsibility vocabulary. It is not a statewide Department of Public Health standing order. Connecticut does not publish a single statewide naloxone standing order; each pharmacy that uses § 20-633d needs its own practitioner agreement on file with DCP .

DCP’s naloxone-prescribing page still lists approved pharmacist programs (UConn School of Pharmacy, Pharmacist’s Letter, Walgreens Connecticut naloxone training). Certification is personal . A new hire cannot use a colleague’s certificate.

Over-the-counter naloxone (FDA, 2023) is a federal nonprescription path for labeled OTC products. It does not repeal § 20-633c or § 20-633d . The prescription path still matters for insurance billing, for formulations that remain prescription, and for the training and record duties that attach when the pharmacist is the prescriber or standing-order dispenser.

Encourage an antagonist with the opioid prescription — P.A. 23-97

CGS § 20-14o(f) , as amended by P.A. 23-97 , binds the prescribing practitioner who issues an opioid-drug prescription to an adult or minor. That practitioner shall:

Discuss the risks of the opioid, including addiction and overdose , and the dangers of combining opioids with alcohol, benzodiazepines, and other CNS depressants , and why the prescription is necessary (and, if applicable, have that discussion with a present parent, guardian, or legal custodian of a minor); and

Encourage the patient (and that present parent or guardian, if applicable) to obtain an opioid antagonist .

That is not a mandatory co-prescription statute, and it is not written as a pharmacist-dispense mandate. It is a 2023 duty on the writer of the opioid prescription. The practical access point is still the pharmacy: a § 20-633c -certified pharmacist can prescribe the antagonist at the same visit, or a § 20-633d pharmacy can dispense it under the standing order. An MPJE stem that shows a new outpatient oxycodone with no antagonist discussion is testing § 20-14o(f) on the prescriber and the pharmacist’s ability to open one of the two pharmacist doors .

Public boxes, vending machines, and host agencies — CGS § 21a-286

P.A. 23-52 (effective June 13, 2023) rebuilt § 21a-286 . A prescribing practitioner , or a pharmacist certified to prescribe an opioid antagonist under § 20-633c , may enter an agreement with a host agency related to distribution and administration. Host agency means a community health organization, emergency medical service provider, government agency, law enforcement agency, or local or regional board of education .

The 2023 expansion added public-access hardware :

A secure box : a container securely affixed in a public location , accessible for public use , displaying DCP-required signage ( P.A. 25-171 added an express DCP-signage subsection). The box holds an intranasally or orally administered antagonist. The agreement must address environmental controls, replenishment, expiration dating and disposal , and signs in the language or languages spoken in the community . Quantity may not exceed what is necessary to serve that community. If the host cannot maintain the box, it and its signs come down as soon as practicable , not later than five days after that discovery.

A vending machine for nasal administration, kept at labeled storage temperature (or independently environmentally controlled), with clear display of overdose signs and symptoms, use instructions, Connecticut opioid-use-disorder treatment information, and a website or QR code covering overdose response.

Placement in a container that also holds an AED or other emergency product is not prohibited.

A syringe services program may include antagonist in its secured machine under a similar agreement. Test strips for pre-use checking may also be distributed from that machine.

The pharmacist or practitioner who signs the agreement shall provide training to persons who will distribute or administer under it. § 21a-286(f) then gives that pharmacist or practitioner immunity from civil damages and from administrative or criminal prosecution for the host agency’s later administration or dispensing.

CGS § 17a-714a is the broader opioid-antagonist immunity and standard-of-care statute. Its title is immunity and no violation of standard of care for prescribing, dispensing, or administering an opioid antagonist. A licensed health care professional may administer an opioid antagonist to any person to treat or prevent an opioid-related drug overdose. Pair that with § 20-633c(c) and § 20-633d(e) when the actor is a pharmacist.

Realistic Connecticut scenario

A certified Waterbury pharmacist sees a patient’s family member who wants naloxone “in case.” Under § 20-633c the pharmacist prescribes , trains , and records . The technician may not complete that prescribing or that training. If the same pharmacy instead holds a § 20-633d agreement with a local physician, the pharmacist dispenses the nasal or auto-injector product under that protocol, trains, records, and mails or transmits a copy of the dispensing record to that physician . DCP already has a copy of the agreement.

A Torrington police department wants a wall-mounted public naloxone box in the lobby. A § 20-633c -certified pharmacist may sign a § 21a-286 host-agency agreement covering storage, restocking, expiration, and bilingual signs. That is not a pharmacy standing order, and it is not CDTM.

An internist electronically sends a first-fill oxycodone and never mentions naloxone. § 20-14o(f)(2) is the internist’s 2023 encourage duty. The pharmacist can still offer to prescribe or standing-order dispense an antagonist at pickup. OTC spray on the shelf does not make the two Chapter 400j statutes optional knowledge.

Official anchors

CGS § 20-633c — pharmacist prescribing; no delegation.

CGS § 20-633d — medical protocol standing order; DCP copy; report back to the practitioner.

CGS § 20-14o — P.A. 23-97 encourage-an-antagonist duty when issuing an opioid prescription.

CGS § 21a-286 — host-agency agreements, secure boxes, vending machines (P.A. 23-52).

DCP naloxone prescribing — approved training programs.